U.S. FDA extends review period of Pfizer’s abrocitinib by three months
Category: #healthcare  By Akshay Kedari  Date: 2021-04-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

U.S. FDA extends review period of Pfizer’s abrocitinib by three months
  • The clinical tests of Pfizer’s drug included adolescents as well as adults with moderate-to-severe atopic dermatitis.
  • The inhibitor had showed positive results and high efficacy for treating eczema.

In recent developments, American multinational pharmaceutical organization, Pfizer Inc. has announced that the U.S. FDA (Food & Drug Administration) has extended the review time for its experimental atopic dermatitis drug, abrocitinib by three months. The regulatory body’s potential approval is expected in the third quarter of this year.

For those uninitiated, abrocitinib is an oral drug developed by Pfizer which selectively inhibits JAK (Janus kinase). JAK inhibitors refer to a type of treatment that targets a range of autoimmune diseases. Apparently, this inhibition is known to modulate various cytokines that are involved in the pathophysiology of atopic dermatitis.

It is also worth mentioning that other JAK inhibitors, including Indianapolis headquartered pharmaceutical company, Eli Lilly & Co’s Olumiant and AbbVie Inc’s Rinvoq have also raised safety concerns leading to subsequent regulatory delays.

If sources are to be believed, the clinical tests of Pfizer’s drug included adolescents as well as adults with moderate-to-severe atopic dermatitis. Although the inhibitor showed positive results and high efficacy for treating eczema, research analysts have been ambivalent about its administration at high doses.

Pfizer mentioned in a statement that the FDA has also extended the priority review timeframe for Xeljanz, the company’s JAK inhibitor that is currently being studied for the treatment of spondylitis.

Reportedly, the preliminary results from a safety trial indicated an increased risk of cancer and severe heart conditions with the use of Xeljanz.

About Pfizer Inc.

Pfizer Inc. is a New York-headquartered research-based biopharmaceutical organization that primarily focuses on the discovery, manufacture, and development of healthcare products. It is known for many popular brands including Celebrex, Bextra, Diflucan, Robitussin, and Advil among others.

Source Credits –

https://www.reuters.com/article/us-pfizer-fda/u-s-fda-extends-review-of-pfizers-experimental-skin-disease-drug-idUSKBN2BU1GZ

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

GOAT Brand Labs secures USD 36 million in Series A funding round
GOAT Brand Labs secures USD 36 million in Series A funding round
By Akshay Kedari

Apparel-centric platform GOAT Brand Labs has reportedly raised USD 36 million in its first funding r...

Suzuki and Daihatsu planning to join Toyota’s electrification venture
Suzuki and Daihatsu planning to join Toyota’s electrification venture
By Akshay Kedari

Japanese automakers Suzuki Motor Corp. along with Daihatsu Motor Co. Ltd. are joining the commercial...

Aquafarming startup Aquaconnect bags USD 4 Mn in pre-Series A funding
Aquafarming startup Aquaconnect bags USD 4 Mn in pre-Series A funding
By Akshay Kedari

Chennai-based aquaculture startup, Aquaconnect has reportedly raised USD 4 million in a pre-Series A...